

# Jane N Winter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11750274/publications.pdf>

Version: 2024-02-01

129  
papers

7,511  
citations

66343

42  
h-index

54911

84  
g-index

129  
all docs

129  
docs citations

129  
times ranked

7672  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	7.0	22
2	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	6.2	7
3	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
4	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 1318-1326.	1.4	85
5	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	3.4	20
6	Cachexia is an independent factor for negative clinical and functional outcomes in lymphoma patients receiving CART therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19504-e19504.	1.6	0
7	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	1.3	17
8	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	1.4	0
9	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	1.4	1
10	Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3566-3566.	1.4	0
11	Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis. <i>Blood</i> , 2021, 138, 231-231.	1.4	2
12	Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial. <i>Blood</i> , 2021, 138, 229-229.	1.4	14
13	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	5.2	22
14	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	17.0	27
15	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	7.0	16
16	A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. <i>Blood</i> , 2020, 136, 44-45.	1.4	2
17	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
18	Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience. <i>Blood</i> , 2020, 136, 14-16.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
20	Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review. <i>Blood</i> , 2020, 136, 9-10.	1.4	3
21	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	0
22	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	7.0	110
23	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1934-1941.	1.3	9
24	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
25	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.5	39
26	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <i>Leukemia and Lymphoma</i> , 2019, 60, 3266-3271.	1.3	4
27	Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. <i>Current Oncology Reports</i> , 2019, 21, 39.	4.0	5
28	Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 436-446.	0.8	3
29	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.4	106
30	NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 245-254.	4.9	45
31	The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience. <i>British Journal of Haematology</i> , 2018, 180, 901-904.	2.5	11
32	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	1.6	102
33	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	64
34	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 608-638.	4.9	81
35	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	1.8	93
36	Outcomes of <i>MYC</i> -associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016, 174, 686-691.	2.5	27

#	ARTICLE	IF	CITATIONS
37	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1274-1281.	4.9	7
38	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	59
39	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	7.0	48
40	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2 (EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4203-4203.	1.4	15
41	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	3.1	19
42	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	3.1	29
43	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016, 128, 4651-4651.	1.4	0
44	Lymphocytosis, lymphadenopathy: benign or malignant?. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 106-110.	2.5	5
45	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.	1.4	242
46	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	4.9	37
47	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	1.8	61
48	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. <i>Leukemia and Lymphoma</i> , 2015, 56, 2895-2901.	1.3	28
49	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	5.5	48
50	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	5.5	21
51	Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e157-e162.	0.4	15
52	Evaluation of NF- $\kappa$ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	5.5	17
53	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	1.8	72
54	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	1.8	35

#	ARTICLE	IF	CITATIONS
55	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	1.8	33
56	Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution. <i>Blood</i> , 2015, 126, 2111-2111.	1.4	0
57	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	7.0	117
58	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	1.4	693
59	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	5.5	112
60	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.0	60
61	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	4.1	32
62	High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender. <i>Blood</i> , 2014, 124, 3046-3046.	1.4	1
63	Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study. <i>Blood</i> , 2014, 124, 3096-3096.	1.4	9
64	a Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 4686-4686.	1.4	3
65	NF- $\kappa$ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 1620-1620.	1.4	0
66	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 143-143.	1.4	1
67	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1681-1690.	27.0	298
68	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	1.4	206
69	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	3.5	142
70	Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo. <i>PLoS ONE</i> , 2013, 8, e58491.	2.5	63
71	STAT3 Expression and Clinical Implications In <i>De Novo</i> Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 365-365.	1.4	1
72	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 213-213.	1.4	0

#	ARTICLE	IF	CITATIONS
73	ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2012, 366, 399-408.	27.0	360
74	Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 589-597.	4.9	90
75	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	1.4	301
76	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 544-544.	1.4	1
77	Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. <i>Blood</i> , 2012, 120, 548-548.	1.4	4
78	Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib. <i>Blood</i> , 2012, 120, 2751-2751.	1.4	0
79	An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database. <i>Blood</i> , 2012, 120, 2656-2656.	1.4	0
80	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , 2012, 120, 2024-2024.	1.4	0
81	A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated High Tumor Burden Indolent Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2012, 120, 1642-1642.	1.4	0
82	Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1020-1058.	4.9	40
83	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	1.6	230
84	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 4499-4499.	1.4	0
85	Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. <i>British Journal of Haematology</i> , 2010, 150, 365-369.	2.5	16
86	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	7.0	25
87	Hypoxia-Inducible Factor-1 $\beta$ Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	1.6	57
88	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. <i>Leukemia and Lymphoma</i> , 2010, 51, 1163-1177.	1.3	13
89	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B-Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.	2.0	88
90	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	1.6	132

#	ARTICLE	IF	CITATIONS
91	Radioimmunoconjugates in Hematopoietic Stem Cell Transplantation. <i>Cancer Treatment and Research</i> , 2009, 144, 299-315.	0.5	2
92	Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1653-1659.	1.6	101
93	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2009, 15, 6462-6471.	7.0	14
94	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52
95	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	1.4	829
96	NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-34.	4.9	11
97	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. <i>Blood</i> , 2009, 114, 2708-2708.	1.4	1
98	Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.. <i>Blood</i> , 2009, 114, 967-967.	1.4	1
99	The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).. <i>Blood</i> , 2009, 114, 1216-1216.	1.4	0
100	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008, 140, 385-393.	2.5	47
101	CD23+ Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 166-177.	0.7	54
102	A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2008, 112, 1000-1000.	1.4	6
103	A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma. <i>Blood</i> , 2008, 112, 236-236.	1.4	9
104	Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies. <i>Blood</i> , 2008, 112, 4989-4989.	1.4	0
105	Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement. <i>Blood</i> , 2007, 109, 844-844.	1.4	1
106	Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. <i>Current Opinion in Hematology</i> , 2007, 14, 360-368.	2.5	14
107	G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , 2007, 137, 545-552.	2.5	71
108	Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 235-241.	2.3	5

#	ARTICLE	IF	CITATIONS
109	Hypoxia-Inducible Factor-Alpha (HIF-1 $\alpha$ ) Activation in Non-Hodgkin's Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).. Blood, 2007, 110, 3587-3587.	1.4	0
110	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 2006, 107, 4207-4213.	1.4	248
111	Current controversies in follicular lymphoma. Blood Reviews, 2006, 20, 179-200.	5.7	12
112	Follicular lymphoma: today's treatments and tomorrow's targets. Expert Opinion on Pharmacotherapy, 2006, 7, 1273-1290.	1.8	7
113	90Y Ibritumomab Tiuxetan (Zevalin $\text{\textcircled{R}}$ ; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.. Blood, 2006, 108, 330-330.	1.4	12
114	Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin's Disease (HD), Indolent Non-Hodgkin's Lymphoma (INHL) and Aggressive Non-Hodgkin's Lymphoma (ANHL).. Blood, 2006, 108, 3332-3332.	1.4	0
115	Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 4634-4642.	1.6	305
116	Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. Blood, 2005, 106, 817-817.	1.4	3
117	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkin's Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. Blood, 2005, 106, 5455-5455.	1.4	0
118	Low-Grade Lymphoma. Hematology American Society of Hematology Education Program, 2004, 2004, 203-220.	2.5	47
119	Combining Yttrium 90 $\text{\textcircled{R}}$ -Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, S22-S26.	2.1	26
120	90Y Ibritumomab Tiuxetan (Zevalin $\text{\textcircled{R}}$ ; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.. Blood, 2004, 104, 1162-1162.	1.4	11
121	Treatment Response to Single Agent Sphingosinyl Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin's Lymphoma (NHL): Subgroup Analyses.. Blood, 2004, 104, 2488-2488.	1.4	0
122	The Lactate Issue Revisited: Novel Feeding Protocols To Examine Inhibition of Cell Proliferation and Glucose Metabolism in Hematopoietic Cell Cultures. Biotechnology Progress, 2000, 16, 885-892.	2.6	55
123	Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma. Journal of Clinical Oncology, 2000, 18, 2762-2771.	1.6	9
124	Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and Long-Term Follow-Up $\text{\textcircled{R}}$ A Report From the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2000, 18, 987-987.	1.6	77
125	Inflammatory pseudotumor of the pancreas. International Journal of Gastrointestinal Cancer, 1995, 18, 277-283.	0.4	24
126	P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. International Journal of Cancer, 1993, 53, 804-811.	5.1	19



#	ARTICLE	IF	CITATIONS
127	Heterogeneity among the non-Hodgkin's lymphomas. implications for autologous bone marrow transplantation with in vitroPurging using monoclonal antibodies. Cancer, 1988, 61, 1082-1090.	4.1	6
128	Monoclonal antibody DLC-48: An effective reagent for use in the depletion of malignant lymphoma from human bone marrow. International Journal of Cancer, 1987, 39, 670-677.	5.1	5
129	Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer, 1985, 56, 443-449.	4.1	68